B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained its Buy rating on Teva Pharmaceutical Industries (NYSE:TEVA) and raised the price target from $18 to $21.
May 30, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has maintained its Buy rating on Teva Pharmaceutical Industries and raised the price target from $18 to $21, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from a reputable analyst firm like B of A Securities is likely to positively influence investor sentiment and drive short-term price appreciation for TEVA.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100